Quest Diagnostics director adds small DGX share stake
Quest Diagnostics director Wright Lassiter III reported a small acquisition of company stock through a dividend reinvestment plan.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Quest Diagnostics director Wright Lassiter III reported a small acquisition of company stock through a dividend reinvestment plan. On April 20, 2026, he acquired 6 shares of common stock at $194.699 per share, bringing his direct holdings to 9,063 shares after the transaction. The filing notes this dividend reinvestment transaction is eligible for deferred reporting under Rule 16a-6, but the director chose to report it early on Form 4.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Small Acquisition | Common Stock | 6 | $194.699 | $1K |
Footnotes (2)
- F1. Represents an award of restricted share units.
- F2. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.
Key Figures
Key Terms
dividend reinvestment plan financial
Rule 16a-6 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did Quest Diagnostics (DGX) report for Wright Lassiter III?
What does Rule 16a-6 mean in the Quest Diagnostics (DGX) Form 4 filing?
Was the Quest Diagnostics (DGX) insider transaction an open-market purchase or a plan reinvestment?
AI-generated analysis. How Rhea-AI works. Not financial advice.